SKIL and breast cancer: In contrast to its reduced expression in primary tumor samples, SnoN have been shown previously to be elevated in esophageal, ovarian and breast cancer cell lines [7], [16], [19], [20], due possibly to gene amplification and/or transcriptional activation.